Are high-density lipoprotein genes and their products targets for therapy?

Current Opinion in Lipidology

Volumn 21, Issue 2, 2010, Pages 157-158

  Motazacker, Mohammad Mahdi ^a   Kastelein, John J ^a   Kuivenhoven, Jan Albert ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER TRIACYLGLYCEROL LIPASE;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; ENZYME DEFICIENCY; GALNT2 GENE; GENE; GENE LOCUS; GENE MUTATION; GENETIC ASSOCIATION; HEART MUSCLE ISCHEMIA; HEPATIC LIPASE DEFICIENCY; HUMAN; LIPC GENE; NOTE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; DRUG DEVELOPMENT; EDITORIAL; GENETICS; METABOLISM;

ATHEROSCLEROSIS; DRUG DISCOVERY; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPOPROTEINS, HDL;

EID: 77957361133     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0b013e3283376923     Document Type: Note

References (18)

1. Plengpanich W, Siriwong S, Khovidhunkit W. Two novel mutations and functional analyses of the CETP and LIPC genes underlying severe hyper-alphalipoproteinemia. Metabolism 2009; 58:1178-1184.
2. Hodoglugil U, Williamson DW, Mahley RW. Polymorphisms in the hepatic lipase gene affect plasma HDL-C levels in a Turkish population. J Lipid Res 2010; 51:422-430.
3. Chasman DI, Pare G, Mora S, et al. Forty-three loci associated with plasma lipoprotein size, concentration, and cholesterol content in genome-wide analysis. PLoS Genet 2009; 5:e1000730.
4. Fan YM, Raitakari OT, Kahonen M, et al. Hepatic lipase promoter C-480T polymorphism is associated with serum lipids levels, but not subclinical atherosclerosis: the Cardiovascular Risk in Young Finns study. Clin Genet 2009; 76:46-53.
5. Feitosa MF, Myers RH, Pankow JS, et al. LIPC variants in the promoter and intron 1 modify HDL-C levels in a sex-specific fashion. Atherosclerosis 2009; 204:171-177.
6. Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J Clin Endocrinol Metab 2009; 94:1264-1273.
7. Edmondson AC, Brown RJ, Kathiresan S, et al. Loss-of-function variants in endothelial lipase are a cause of elevated HDL cholesterol in humans. J Clin Invest 2009; 119:1042-1050.
8. Tanaka H, Ishida T, Johnston TP, et al. Role of endothelial lipase in plasma HDL levels in a murine model of hypertriglyceridemia. J Atheroscler Thromb 2009; 16:327-338.
9. Qiu G, Hill JS. Endothelial lipase promotes apolipoprotein AI-mediated cholesterol efflux in THP-1 macrophages. Arterioscler Thromb Vasc Biol 2009; 29:84-91.
10. Nijstad N, Wiersma H, Gautier T, et al. Scavenger receptor BI-mediated selective uptake is required for the remodeling of high density lipoprotein by endothelial lipase. J Biol Chem 2009; 284:6093-6100.
11. Edmondson A, Khera A, Khetarpal S, et al. Functional characterization of GALNT2, a novel GWAS locus associated with HDL-C [abstract]. In: Proceedings of 59th Annual meeting of the American Society of Human Genetics; 24 October 2009.
12. Nakayama K, Bayasgalan T, Yamanaka K, et al. Large scale replication analysis of loci associated with lipid concentrations in a Japanese population. J Med Genet 2009; 46:370-374.
13. Tai ES, Sim XL, Ong TH, et al. Polymorphisms at newly identified lipid-associated loci are associated with blood lipids and cardiovascular disease in an Asian Malay population. J Lipid Res 2009; 50:514-520.
14. Naj AC, West M, Rich SS, et al. Association of scavenger receptor class B type I polymorphisms with subclinical atherosclerosis: the Multi-Ethnic Study of Atherosclerosis. Circulation: Cardiovascular Genetics 2009 [Epub ahead of print]. doi: 10.1161/CIRCGENETICS.109.903195.
15. Zhang Y, Yin L, Anderson J, et al. Identification of novel pathways that control farnesoid X receptor (FXR)-mediated hypocholesterolemia. J Biol Chem 2010; 285:3035-3043.
16. Wiersma H, Nijstad N, Gautier T, et al. Scavenger receptor BI (SR-BI) facilitates hepatic very low density lipoprotein (VLDL) production in mice. J Lipid Res 2009 [Epub ahead of print]. doi: 10.1194/jlr.M000844.
17. Masson D, Koseki M, Ishibashi M, et al. Increased HDL cholesterol and apoA-I in humans and mice treated with a novel SR-BI inhibitor. Arterioscler Thromb Vasc Biol 2009; 29:2054-2060.
18. Willer CJ, Sanna S, Jackson AU, et al. Newly identified loci that influence lipid concentrations and risk of coronary artery disease. Nat Genet 2008; 40:161 - 169. (Pubitemid 351171403)